Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis

Ulcerative Colitis Clinical Trial

— PREDIRESPUC  

Official title:

Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03724929
• Other study ID #: 1708213
• Secondary ID: 2018-001051-12
• Status: Terminated
• Phase: N/A
• Start date: March 4, 2019
• Est. completion date: June 28, 2022

Study information

• Verified date: May 2023
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vedolizumab (VDZ) is a monoclonal antibody that binds to the heterodimer α4β7 integrin and which has shown its efficacy in Ulcerative Colitis (UC) by inducing and maintaining clinical response/remission. The French marketing authorization was obtained for Ulcerative Colitis in patients in failure with anti-Tumor Necrosis Factor (anti-TNF) agents. In the pivotal study, correlation between drug levels and clinical response during induction and maintenance therapy were reported. Moreover, in 3.7% of cases, anti-vedolizumab antibodies were reported during the time-course and 1% had samples that were persistently positive. Up to now, data on the pharmacologic VDZ parameters are scarce and the relationships as well as the predictive value of the measurement of VDZ concentrations and VDZ monoclonal antibodies (mAbs) during the induction and maintenance phases remains unknown. It could be of paramount interest to early identify UC patients under VDZ who will be responders to VDZ induction and to identify those who will achieve clinical remission under maintenance therapy with VDZ.

Description:

The contribution of the pharmacokinetic studies of monoclonal antibodies (anti-TNF antibodies currently) has assumed increasing importance of its use in clinical practice. Therapeutic algorithms for both Infliximab (IFX) and Adalimumab (ADA) have been published and are used by many expert teams in the event of loss of therapeutic response. Similarly, the concentrations are assuming important in the indication of therapeutic de-escalation. Lastly, the assays may predict medium-term therapeutic response to treatment and thus enable proposal of preventive therapeutic changes (5). The Gemini 1 study (phase 3 vedolizumab vs. placebo in Ulcerative Colitis) showed a correlation between drug levels and clinical response during induction and maintenance therapy. Moreover, in 3.7% of cases, anti-vedolizumab antibodies were reported during the time-course and 1% had samples that were persistently positive. (1). In addition, we have decided to assess the clinical response to VDZ induction at W10 (Week 10), as the Gemini III trial for Crohn Disease (Crohn Disease) have reported, among patients who had experienced previous Tumor Necrosis Factor (TNF) antagonist failure, that 15% of those given vedolizumab versus 12% under placebo were in remission at W6 (P=0.433) whereas a higher proportion of them were in remission (26%) under VDZ when compared with the placebo arm (12%) at week 10. Therefore, in clinically non-responders at W10, an additional dose of 300 mg of VDZ will be infused at W10 and every four weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 67
• Est. completion date: June 28, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged over 18 years

• Men or non-pregnant women

• Patients with a diagnosis of ulcerative colitis who requires to start VDZ

• Moderate to severe active ulcerative colitis defined as a total mayo score ranging from 6 to 12 and endoscopic Mayo score above 1

• UC patients with previous failure with TNF antagonist agents and unacceptable side-effects from steroids, and/or immunosuppressive agents (i.e., azathioprine, 6-mercaptopurine, or methotrexate).

• oral prednisone, are allowed at stable dose for at least 4 weeks-before inclusion. Concomitant immunosuppressive agents, mesalamine, are allowed at stable dose for at least three months before inclusion. Steroid tapering has to be set up at Week 6 after starting VDZ, according to the European Crohn's and Colitis Organisation (ECCO) recommendations.

• Informed written consent given.

Exclusion Criteria:

• Existing pregnancy, lactation, or intended pregnancy within the next 15 months

• Minors or History of disease, including mental/emotional disorder that might interfere with their participation in the study

• Serious secondary illnesses of an acute or chronic nature, which in the opinion of the investigator renders the patient unsuitable for inclusion into the study

• Inability to comply with the protocol requirements

• Inability to fill in the diary cards during the last 3 days before each visit

• Severe Acute UC needed hospitalisation

• Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years)

• Short bowel syndrome

• Previous treatments with vedolizumab, natalizumab, efalizumab or rituximab.

• Previous treatment with adalimumab within 30 days prior enrollment or infliximab and certolizumab pegol within 60 days before enrollment (This period may be shortened in the opinion of the investigator.)

• Prior extensive colonic resection, obstructive (symptomatic) intestinal stricture, abdominal abscess, active or latent tuberculosis,

• Clostridium difficile superinfection;

• Indeterminate colitis

• Concomitant leukocyte apheresis.

• Any contraindication to vedolizumab therapy

• Patients who denied the protocol, not ability to accept or sign consent of the protocol

• Subject involved in another interventional clinical trial

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Procedure:
• Blood sample
Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.

Device:
• Rectosigmoidoscopy
Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.

Locations

Country	Name	City	State
France	CHU Amiens	Amiens
France	CHU Kremlin Bicêtre	Le Kremlin-Bicêtre
France	Chu L'Archet	Nice
France	Ch Lyon Sud	Pierre-Bénite
France	CHU Saint-Etienne	Saint-Étienne

Sponsors (3)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Takeda, Theradiag

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vedolizumab concentration at week 6	Determine the optimal threshold of VDZ serum concentration measured at W6 capable to predict the clinical response at week 10 with VDZ.	Week 6
Secondary	Vedolizumab concentration at week 14	Determine the optimal threshold of VDZ serum concentration measured at W14 capable to predict the clinical response at week 52 with VDZ.	Week 14
Secondary	vedolizumab concentration and anti-vedolizumab antibodies concentrations at week 2	Investigating whether the pharmacokinetic parameters of vedolizumab (serum trough levels concentrations, specific antibody concentrations) measured at W2 are predictive of a clinical response and clinical remission at W10.	Week 2
Secondary	vedolizumab concentration and anti-vedolizumab antibodies concentrations at week 14	Investigating whether the pharmacokinetic parameters of vedolizumab (serum trough levels concentrations, specific antibody concentrations) measured at W14 are predictive of a clinical response and clinical remission at W52.	Week 14
Secondary	Vedolizumab concentration at week 6 and mucosal healing	Analyzing the value of VDZ trough levels measured at W6 to predict mucosal healing at W10 under induction therapy with VDZ in UC	Week 6
Secondary	Vedolizumab concentration at week 14 and mucosal healing	Analyzing the value of VDZ trough levels measured at W14 to predict mucosal healing at W52 under induction therapy with VDZ in UC	Week 14
Secondary	intra and inter-individual heterogeneity of VDZ levels	Investigating the intra and inter-individual heterogeneity of VDZ levels within the time-course of VDZ therapy, including the induction and maintenance phases.	Week 52
Secondary	Proportion of loss of clinical response	Comparing the proportion of loss of clinical response in responder UC patients as well as in primary non-responders requiring VDZ dose-intensification within one-year of follow-up	Week 52
Secondary	Variation of serum VDZ	Assessing the relationships between the variation of serum VDZ trough levels pre- and post-optimization (delta) and the clinical response in primary non-responder patients requiring additional infusions of VDZ.	Week 52
Secondary	vedolizumab concentration and anti-vedolizumab antibodies concentrations	Comparing the whole and individual pharmacokinetic parameters (vedolizumab concentration and anti-vedolizumab antibodies concentrations) between patients achieving a clinical remission or not at W52	Week 52